FG001

FG001 is a fluorescent dye that makes tumor cells glow under near-infrared light during brain surgery [1]. It's a small peptide called AE105 (which binds a protein called uPAR found on aggressive tumor cells) tethered to indocyanine green, an FDA-approved dye used for cardiac and liver imaging since 1959. The Phase 2 trial at Rigshospitalet in Copenhagen (NCT06684795) is testing whether it lights up meningiomas and low-grade gliomas clearly enough for surgeons to see the tumor margin in real time [3]. This is the gap behind 5-ALA (Gleolan), the only approved fluorescence agent for brain surgery, which works for high-grade gliomas but fails in the slower-growing tumors where surgical precision matters most [4]. The drug is developed by FluoGuide A/S, a small Danish biotech listed on Nasdaq First North (a Nordic SME exchange with thin float and limited US analyst coverage); Rigshospitalet is just the trial site, despite what ClinicalTrials.gov suggests. Phase 1/2 data in high-grade gliomas (35 patients, Neurosurgery 2025) and oral cancer (Theranostics 2025) showed the agent reaches tumor and fluoresces with no serious adverse events [1, 2]. This trial asks whether that signal holds in tumors where MRI contrast is worst - and whether the dura, which itself carries some uPAR, will confound the meningioma readout.

Novel compound, Phase 2, currently recruiting against a 40-patient target at a single Danish site [3]. No FDA designations identified. FluoGuide hasn't pursued breakthrough or fast track, which is consistent with a CE-mark-first European regulatory path (CE mark = European regulatory approval, analogous to FDA clearance). A US filing could potentially use 505(b)(2) given ICG's safety record, though the regulatory pathway for optical imaging conjugates is not standardized and FG001 - as a new molecular entity combining ICG with the AE105 peptide - could equally require a standard NDA or, if classified as a drug-device combination with the NIR camera system, a CDER/CDRH joint review. The molecule itself isn't truly novel-in-human. First-in-human data in malignant glioma (35 patients, single IV dose before craniotomy) published in Neurosurgery in 2025 reported successful intraoperative tumor visualization with no serious drug-related adverse events [1]. A separate Phase 2 in oral and oropharyngeal squamous cell carcinoma published in Theranostics in 2025 showed tumor-specific fluorescence and supported the uPAR-targeting mechanism across tumor types [2]. So this Phase 2 in meningiomas plus low-grade gliomas is a label-expansion-style study into the indication where 5-ALA doesn't work, not a true first study. Primary completion is not publicly disclosed, but with n=40 at one site and a tumor-visualization readout rather than a survival readout, expect readout late 2026 to early 2027. Status to watch: any pivot to multi-site enrollment, which would signal that FluoGuide and a partner are setting up the registrational trial.

Two parts to the molecule. The first is indocyanine green (ICG), a fluorescent dye that has been FDA-approved since 1959 for cardiac output, liver function, and vascular imaging. It absorbs and emits near-infrared light (700-900nm), which passes through tissue better than visible light, so surgeons can see fluorescence 5-10mm below the surface (depending on tissue type) using a standard near-infrared camera. That depth matters clinically: it's the range over which a surgeon can detect infiltrating tumor cells at the resection margin, not just gross tumor surface - which is precisely the surgical problem FG001 is designed to solve. The second part is AE105, a 9-amino-acid peptide that binds uPAR (urokinase plasminogen activator receptor) - a protein on the cell surface that helps cells break down the matrix around them, which is how tumor cells invade nearby tissue [1]. uPAR is the target because it's switched on in aggressive tumor cells and in the stromal cells at the invasive edge of tumors, where the cancer is spreading into normal brain. Healthy adult brain has almost no uPAR. So FG001 should bind tumor and tumor-adjacent tissue while skipping normal brain, producing exactly the contrast surgeons need. The biology of uPAR in cancer invasion is decades-validated by pathology, knockout mice, and human IHC studies. The bet is that this validation translates from microscope slides to clean optical contrast in the operating room. The 35-patient high-grade glioma study showed tumor fluorescence at the cellular level on excised tissue, with tumor-to-background ratios sufficient for surgical decision-making [1]. Whether that ratio holds in low-grade gliomas, which are less metabolically active and where IHC literature suggests lower (though non-zero) uPAR expression than in WHO grade 3-4 disease, is the open question - no published quantitative comparison of FG001 binding across WHO grades yet exists.

Single-arm, single-site, open-label Phase 2 at Rigshospitalet in Copenhagen, enrolling 40 patients scheduled for surgical resection of either a presumed meningioma or a presumed low-grade glioma (NCT06684795) [3]. FG001 is administered IV before craniotomy. The primary objective is intraoperative visualization - specifically, whether the surgeon can identify tumor tissue using the fluorescence signal and whether the signal correlates with histology on the excised specimen. No comparator arm; no survival or progression endpoint. The right way to read this trial: it's a feasibility and biomarker study, not a registrational one. Two scientific questions are on the table. First, does FG001 light up meningiomas without lighting up the surrounding dura (the membrane around the brain that meningiomas grow from, which itself expresses some uPAR)? Second, does the signal hold in WHO grade 2 low-grade gliomas (slow-growing, considered low-risk but still requiring surgery), which produce less uPAR than the grade 3-4 tumors where FG001 already worked? A 40-patient single-site study can answer both. What it cannot answer is whether using FG001 actually improves extent of resection, recurrence rates, or neurological outcomes versus standard neuronavigation plus intraoperative MRI. That's the next trial. It would need randomization, multiple sites, and a partner with operating-room sales muscle. On the hardware side, FG001 is designed to work with the NIR-capable surgical microscopes and exoscopes already installed in many neurosurgery ORs for ICG angiography (Zeiss KINEVO/TIVATO, Leica ARveo, Stryker SPY-PHI), so it does not require a dedicated imaging platform - a meaningful adoption advantage if approved.

Our model gives this drug a 6% chance of eventually being approved. That number starts from the historical approval rate for Phase 2 drugs in this area - about 13% - then adjusts based on ten specific facts about the trial and sponsor. The estimate gets a boost from the trial's non-randomized design and open-label blinding, but is pulled down by the sponsor's thin approval record and weak earlier-phase results. The remaining facts are close to average for this stage, so they leave the estimate roughly where it started.

Efficacy risk lives in meningiomas. The dura - the membrane around the brain that meningiomas grow from - expresses some uPAR itself. If FG001 lights up both tumor and adjacent dura at similar intensity, the contrast that matters for surgery disappears and the indication shrinks back to gliomas only. Low-grade gliomas have less metabolic activity and probably less uPAR than the high-grade tumors where FG001 already worked. Whether the signal is strong enough in WHO grade 2 tumors is genuinely unknown going in. Fluorescein sodium, used off-label at some glioma centers (notably the YELLOW 2 / FLUOGLIO experience), has similar signal-quality limitations in low-grade disease - FG001's uPAR targeting is the proposed differentiator, but head-to-head data don't exist and won't from this trial. Safety risk is low. ICG has been used in millions of patients since 1959 with a known anaphylaxis rate around 1 in 40,000. AE105 is a short peptide given as a single dose, so no chronic exposure and no realistic immunogenicity concern at one administration. The first-in-human study reported no serious drug-related events across 35 patients [1]. Execution risk is concentrated. FluoGuide A/S runs lean - Nasdaq First North-listed micro-cap, single asset in clinic, financed in discrete equity raises rather than from operations, so any enrollment slippage or unexpected protocol amendment increases dilution risk. The trial is at one Danish hospital, which raises generalizability questions if regulators want multi-site data before a label. IP position is a watch item: AE105 and the FG001 conjugate appear covered by FluoGuide / University of Copenhagen patent family, but the exact composition-of-matter and use-in-imaging claim expiries are not consistently disclosed in public filings - an acquirer will diligence this hard. Commercial risk: even if approved, the market is small. US meningioma surgeries run around 30,000 per year and low-grade glioma surgeries around 10,000. Reimbursement for intraoperative imaging agents took 5-ALA years to sort out in the US, and FG001 would face the same payer learning curve [4].

Worth watching, with a tight definition of what would make this a signal. The science is well-grounded: uPAR is a validated cancer-invasion target, ICG is FDA-approved, and the first-in-human glioma data is positive [1]. The trial isn't registrational, but a positive readout sets up a registration trial and a CE-mark filing. A negative readout in meningiomas (signal contamination from dura) would not kill the program; it would refocus it on gliomas, which is still a real indication. The specific data point to watch: tumor-to-background fluorescence ratio in WHO grade 2 low-grade gliomas. In the high-grade glioma study that ratio was clinically usable [1]. If it holds at grade 2, this is real. If it drops by half, the addressable market shrinks back to grade 3-4 tumors, where 5-ALA already exists and is reimbursed. Commercial math: at a per-dose price comparable to Gleolan (~$1,500), peak US penetration of 50% in meningiomas and 30% in low-grade gliomas implies a ~$25-35M US annual revenue ceiling - a tuck-in acquisition target, not a standalone commercial story. Ex-US expands the number modestly but doesn't change the category. Check back in late 2026 or early 2027 for primary completion. The company to track is FluoGuide A/S (Nasdaq First North: FLUO), not Rigshospitalet - small float, news-driven, vulnerable to financing pressure but also acquirable. Strategic optionality is real: Stryker, Leica, and Carl Zeiss Meditec sell the NIR cameras that read FG001's signal, and a tuck-in acquisition by either of them or by a surgical-oncology player like Medtronic or Olympus is plausible once Phase 2 reads out cleanly.